MX2023004835A - Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-car boxilico que lo comprende. - Google Patents
Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-car boxilico que lo comprende.Info
- Publication number
- MX2023004835A MX2023004835A MX2023004835A MX2023004835A MX2023004835A MX 2023004835 A MX2023004835 A MX 2023004835A MX 2023004835 A MX2023004835 A MX 2023004835A MX 2023004835 A MX2023004835 A MX 2023004835A MX 2023004835 A MX2023004835 A MX 2023004835A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline particles
- pharmaceutical composition
- pyrazole
- indole
- cyano
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende partículas cristalinas que comprenden el compuesto de Fórmula 1 o una sal farmacéuticamente aceptable de este que incluye el compuesto de Fórmula 2 a continuación en una cantidad de 0,2% en peso o menos. Las partículas cristalinas según la presente invención tienen un tamaño, forma y distribución que mejoran la uniformidad y fluidez, además de estar optimizado para la entrada en el proceso de preparación del medicamento terminado, lo cual aumenta la uniformidad del contenido en el proceso de preparación del producto terminado y minimiza la rotura durante la compresión en comprimidos y, por lo tanto, puede usarse como un medicamento de materia prima adecuado para el proceso de preparación del medicamento terminado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200145750 | 2020-11-04 | ||
| PCT/KR2021/015708 WO2022098057A1 (ko) | 2020-11-04 | 2021-11-02 | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004835A true MX2023004835A (es) | 2023-05-10 |
Family
ID=81458100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004835A MX2023004835A (es) | 2020-11-04 | 2021-11-02 | Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-car boxilico que lo comprende. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240000750A1 (es) |
| EP (1) | EP4218755A4 (es) |
| JP (1) | JP7667270B2 (es) |
| KR (1) | KR20220060488A (es) |
| CN (1) | CN116456979A (es) |
| AR (1) | AR123999A1 (es) |
| AU (1) | AU2021374260B2 (es) |
| CA (1) | CA3194595A1 (es) |
| CL (1) | CL2023001025A1 (es) |
| CO (1) | CO2023007110A2 (es) |
| MX (1) | MX2023004835A (es) |
| MY (1) | MY208699A (es) |
| PE (1) | PE20240139A1 (es) |
| TW (3) | TWI848241B (es) |
| WO (1) | WO2022098057A1 (es) |
| ZA (1) | ZA202305840B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021392532B2 (en) * | 2020-12-01 | 2025-04-10 | Lg Chem, Ltd. | Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same |
| TWI896975B (zh) * | 2020-12-01 | 2025-09-11 | 南韓商Ｌｇ化學股份有限公司 | 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法 |
| TWI903066B (zh) * | 2021-04-16 | 2025-11-01 | 南韓商Ｌｇ化學股份有限公司 | 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之口服用複合調配物 |
| TWI822151B (zh) * | 2021-07-02 | 2023-11-11 | 南韓商Ｌｇ化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19602505A1 (de) * | 1996-01-25 | 1997-07-31 | Merck Patent Gmbh | 1-(Pyrazol-4-Indol-3-yl)-Piperidine |
| KR101502957B1 (ko) * | 2007-04-11 | 2015-03-16 | 깃세이 야쿠힌 고교 가부시키가이샤 | (아자)인돌 유도체 및 그 의약 용도 |
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| KR20200145750A (ko) | 2019-06-19 | 2020-12-30 | 한국전자통신연구원 | 시공간 예측을 이용한 비디오 부/복호화 방법 및 장치 |
-
2021
- 2021-11-02 KR KR1020210148950A patent/KR20220060488A/ko not_active Ceased
- 2021-11-02 EP EP21889522.5A patent/EP4218755A4/en not_active Withdrawn
- 2021-11-02 CA CA3194595A patent/CA3194595A1/en active Pending
- 2021-11-02 MX MX2023004835A patent/MX2023004835A/es unknown
- 2021-11-02 TW TW110140777A patent/TWI848241B/zh active
- 2021-11-02 WO PCT/KR2021/015708 patent/WO2022098057A1/ko not_active Ceased
- 2021-11-02 JP JP2023526427A patent/JP7667270B2/ja active Active
- 2021-11-02 CN CN202180072645.4A patent/CN116456979A/zh active Pending
- 2021-11-02 MY MYPI2023002328A patent/MY208699A/en unknown
- 2021-11-02 PE PE2023001502A patent/PE20240139A1/es unknown
- 2021-11-02 AU AU2021374260A patent/AU2021374260B2/en active Active
- 2021-11-02 TW TW113117906A patent/TW202509020A/zh unknown
- 2021-11-02 TW TW112120157A patent/TWI884455B/zh active
- 2021-11-02 US US18/251,646 patent/US20240000750A1/en active Pending
- 2021-11-04 AR ARP210103066A patent/AR123999A1/es unknown
-
2023
- 2023-04-10 CL CL2023001025A patent/CL2023001025A1/es unknown
- 2023-05-30 CO CONC2023/0007110A patent/CO2023007110A2/es unknown
- 2023-05-31 ZA ZA2023/05840A patent/ZA202305840B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4218755A1 (en) | 2023-08-02 |
| TWI884455B (zh) | 2025-05-21 |
| TWI848241B (zh) | 2024-07-11 |
| MY208699A (en) | 2025-05-25 |
| JP2023548160A (ja) | 2023-11-15 |
| CA3194595A1 (en) | 2022-05-12 |
| AU2021374260B2 (en) | 2024-12-19 |
| AU2021374260A9 (en) | 2025-01-16 |
| TW202225158A (zh) | 2022-07-01 |
| TW202336015A (zh) | 2023-09-16 |
| AU2021374260A1 (en) | 2023-06-01 |
| PE20240139A1 (es) | 2024-01-30 |
| TW202509020A (zh) | 2025-03-01 |
| WO2022098057A1 (ko) | 2022-05-12 |
| CO2023007110A2 (es) | 2023-07-10 |
| JP7667270B2 (ja) | 2025-04-22 |
| CL2023001025A1 (es) | 2023-12-11 |
| ZA202305840B (en) | 2024-09-25 |
| EP4218755A4 (en) | 2024-03-27 |
| US20240000750A1 (en) | 2024-01-04 |
| AR123999A1 (es) | 2023-02-01 |
| CN116456979A (zh) | 2023-07-18 |
| KR20220060488A (ko) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202305840B (en) | Method for preparing crystalline particles of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid, and pharmaceutical composition comprising same | |
| DE60004649T2 (de) | Verfahren zur herstellung nicht-hygroscopische l (-) - carnitine salze | |
| KR101612197B1 (ko) | 부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법 | |
| MXPA02004603A (es) | Sales estables de nuevos derivados de 3, 3-difenilpropilaminas. | |
| KR101324862B1 (ko) | 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
| KR101399514B1 (ko) | 폴라프레징크를 함유하는 안정한 정제 제형 | |
| SI2800558T1 (en) | A stable pharmaceutical formulation for oral administration comprising levocetirizines or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| MX2023015139A (es) | Inhibidores de mutacion de her2. | |
| MX2024011914A (es) | Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida | |
| JPWO2019146642A1 (ja) | γ−アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法 | |
| MX2014012178A (es) | Metodos para producir clorhidrato de anamorelina que tiene contenido de cloruro controlado. | |
| CN115364065A (zh) | 富马酸伏诺拉生片 | |
| CN103393611A (zh) | 一种盐酸伊伐布雷定片剂及其制备方法 | |
| CN105534980B (zh) | 瑞格列奈盐酸二甲双胍的药物组合物及其制剂工艺 | |
| CN108245516B (zh) | 一种含瑞舒伐他汀钙的药物组合物及其制备方法 | |
| CZ2011872A3 (cs) | Farmaceutická formulace prasugrelu hydrobromidu | |
| CN114224890A (zh) | 一种硫酸羟氯喹药物组合物及制备方法 | |
| CA2559670A1 (en) | Stable amlodipine maleate formulations | |
| JP2022007461A (ja) | トルバプタン含有口腔内崩壊錠 | |
| DD218096A5 (de) | Verfahren zur herstellung von n-(3-triflourmethylphenyl)-n-propargyl-piperazin | |
| CN107811981A (zh) | 一种比拉斯汀组合物 | |
| EP2561864B1 (en) | Coated tablet comprising tianeptine and process for preparation thereof | |
| WO2025210469A3 (en) | Process of preparing remibrutinib substantially free of nitrosamine impurity | |
| EP2749269A1 (en) | Process for the preparation of adsorbates of imatinib | |
| EP1338275B1 (en) | Pharmaceutical composition, the use thereof and method for producing said composition |